Genprex begins treating patients in two new lung cancer trials, continues third

Genprex, Inc.

Opened enrollment and began treating patients in two new lung cancer clinical trials in 2024.
Continues treating patients in a third lung cancer clinical trial.
Partnered with community-based oncology practices to broaden clinical study reach.
Expanded preclinical programs into new indications; presented positive data at major cancer conference.
Strengthened global IP estate for lead drug candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.